Ipratropium Bromide Inhalation Aerosol
NDC Package 17270-0401-0

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Ipratropium Bromide Inhalation aerosols is ipratropium is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). This formulation utilizes a aerosol delivery system. Marketed by Armstrong Pharmaceuticals, Inc., this product is identified by NDC 17270-0401 and is authorized under FDA application ANDA217953.

Identification & Billing

NDC Package Code
17270-0401-0
Package Description
1 CANISTER in 1 CARTON / 200 AEROSOL in 1 CANISTER
Product Code
17270-0401
11-Digit Billing Format
17270040100
Billing Unit
GM - Billing unit of "gram" is used when a product is measured by its weight.
RxNorm Crosswalk
  • RxCUI: 836343 - ipratropium bromide 17 MCG/INHAL Metered Dose Inhaler, 200 Actuations
  • RxCUI: 836343 - 200 ACTUAT ipratropium bromide 0.017 MG/ACTUAT Metered Dose Inhaler
  • RxCUI: 836343 - ipratropium bromide 0.017 MG/ACTUAT Metered Dose Inhaler, 200 ACTUAT
  • RxCUI: 836343 - ipratropium bromide 17 MCG/ACTUAT Metered Dose Inhaler, 200 ACTUAT

Clinical Specifications

Proprietary Name
Ipratropium Bromide Inhalation
Non-Proprietary Name
Ipratropium Bromide Inhalation
Substance Name
Ipratropium Bromide
Dosage Form
Aerosol - A product that is packaged under pressure and contains therapeutically active ingredients that are released upon activation of an appropriate valve system; it is intended for topical application to the skin as well as local application into the nose (nasal aerosols), mouth (lingual aerosols), or lungs (inhalation aerosols).
Administration Route
Respiratory (inhalation) - Administration within the respiratory tract by inhaling orally or nasally for local or systemic effect.
Active Ingredient(s)
IPRATROPIUM BROMIDE 17 ug/1
Pharmacologic Class
Usage Information
Ipratropium is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. For preventing symptoms of lung disease, this medication must be used regularly to be effective. Use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) for wheezing or sudden shortness of breath unless otherwise directed by your doctor. Ipratropium does not work as fast as your quick-relief inhaler, but may sometimes be used to relieve symptoms of wheezing or sudden shortness of breath if so prescribed by your doctor.

Regulatory & Marketing

Labeler Name
Armstrong Pharmaceuticals, Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA217953
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
04-16-2026
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 17270-0401-0 identifies a specific commercial package of 1 canister in 1 carton / 200 aerosol in 1 canister of Ipratropium Bromide Inhalation, a human prescription drug labeled by Armstrong Pharmaceuticals, Inc.. This aerosol is formulated for respiratory (inhalation) use and contains ipratropium bromide as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Armstrong Pharmaceuticals, Inc. on April 16, 2026. The current certification is valid through December 31, 2027.

What are the primary indications for this medication?

Ipratropium is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. For preventing symptoms of lung disease, this medication must be used regularly to be effective. Use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) for wheezing or sudden shortness of breath unless otherwise directed by your doctor. Ipratropium does not work as fast as your quick-relief inhaler, but may sometimes be used to relieve symptoms of wheezing or sudden shortness of breath if so prescribed by your doctor.

How is this Armstrong Pharmaceuticals, Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 17270040100. Quantities are measured in per "gm or gram", products billed per gram are products measured by weight.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
17270-0401-0
11-Digit CMS (5-4-2)
17270-0401-00

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.